11β,13-Dihydrolactucopicrin
11β,13-Dihydrolactucopicrin is a sesquiterpene lactone and the main bitter component of chicory root. 11β,13-Dihydrolactucopicrin inhibits yeast α-glucosidase activity (IC50 = 27.49 μM) and inhibits Crz1 activation and nuclear accumulation. 1β,13-Dihydrolactucopicrin possesses blood-brain barrier penetration capacity in an in vitro HBMEC blood-brain barrier model and can generate cysteine-conjugated metabolites within brain microvascular endothelial cells. 11β,13-Dihydrolactucopicrin can regulate the lncRNA H19/miR-21-3p signaling axis; it upregulates the expression of ABCG2 and lncRNA H19, downregulates miR-21-3p, inhibits the release of IL-6, TNF-α, and hs-CRP pro-inflammatory mediators, and alleviates urate-induced inflammatory injury in renal epithelial cells. 11β,13-Dihydrolactucopicrin can be used in research on diabetes and renal urate deposition.
For research use only. We do not sell to patients.
- CAS No.: 125519-47-3
- Formula: C23H24O7
- Molecular Weight:412.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
α‑glucosidase 27.49 μM (IC50) |
IL-6 |
TNF-α |
In Vitro
11β,13-dihydrolactucopicrin (10 μM; 4 h) exhibited moderate permeability in Caco-2 monolayer cells, with the apical concentration decreasing by 29.9%, and no cysteine adduct was formed[1].
11β,13-dihydrolactucopicrin (12.5-100 μM; 3 h) has a maximum non-toxic concentration of 12.5 µM in Saccharomyces cerevisiae[1].
11β,13-dihydrolactucopicrin exhibited moderate inhibitory activity against the calcineurin-Crz1 pathway in Saccharomyces cerevisiae YAA5, with an inhibition rate of 26% at 12.5 µM[1].
11β,13-Dihydrolactucopicrin (compound 5) inhibited yeast α-glucosidase with an IC50 of 27.49 μM, showing limited inhibitory activity, possibly because its phenyl group hinders binding to the enzyme[2].
11β,13-Dihydrolactucopicrin (predicted by molecular docking) showed good binding activity with the ABCG2 protein, exhibiting the lowest binding energy among the tested compounds[3].
11β,13-dihydrolactucopicrin (5 μM; 2 h) can be transported across the in vitro BBB model of HBMEC, with a transport percentage between 10% and 20%[4].
11β,13-Dihydrolactucopicrin (10 μM; 24 h) attenuates inflammation and enhances ABCG2 expression in UA- and LPS-stimulated NRK-52E cells, while uniquely upregulating lncRNA H19 and downregulating miR-21-3p[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NRK-52E
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly suppressed IL-6 levels.
Significantly decreased hs-CRP levels.
Upregulated ABCG2 protein expression.
Elevated ABCG2 mRNA expression.
Uniquely and significantly upregulated lncRNA H19 expression.
Markedly downregulated miR-21-3p expression.
-
Cell Line:NRK-52E
-
Concentration:10, 50, 100, 200, 500 μM
-
Incubation Time:24 h
-
Result:Assessed viability of NRK-52E cells to determine appropriate non-cytotoxic concentrations for subsequent experiments.
Chemical Information
-
CAS No. 125519-47-3
-
Molecular Weight 412.44
-
Formula C23H24O7
-
SMILES
C(O)C=1[C@@]2([C@@]3([C@@]([C@@H](OC(CC4=CC=C(O)C=C4)=O)CC(C)=C2C(=O)C1)([C@H](C)C(=O)O3)[H])[H])[H]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)